Lung cancer screening by low-dose CT scan in France: final results of the DEP KP80 study after three rounds.

IF 9.7 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

EBioMedicine Pub Date : 2024-11-01 Epub Date: 2024-10-12 DOI:10.1016/j.ebiom.2024.105396

Olivier Leleu, Nicolas Storme, Damien Basille, Marianne Auquier, Valerie Petigny, Pascal Berna, Alexia Letierce, Sebastien Couraud, Julie de Bermont, Bernard Milleron, Vincent Jounieaux

{"title":"Lung cancer screening by low-dose CT scan in France: final results of the DEP KP80 study after three rounds.","authors":"Olivier Leleu, Nicolas Storme, Damien Basille, Marianne Auquier, Valerie Petigny, Pascal Berna, Alexia Letierce, Sebastien Couraud, Julie de Bermont, Bernard Milleron, Vincent Jounieaux","doi":"10.1016/j.ebiom.2024.105396","DOIUrl":null,"url":null,"abstract":"Background: In prior randomised controlled trials, lung cancer screening using low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality and overall mortality. Despite these results, organised screening in France remains a challenge. This study assessed the feasibility and efficacy of lung cancer screening within a real-life context in a French administrative territory.Methods: DEP KP80 was a single-arm prospective study. Participants aged between 55 and 74 years, smokers or former smokers of ≥30 pack-years, were recruited. An annual LDCT scan was scheduled and three rounds were performed. Subjects were selected by general practitioners or pulmonologists, who checked the inclusion criteria and prescribed the CT scan.Findings: Between March 2016 and February 2020, 1254 participants were enrolled. Overall, 945 (75.4%) participants underwent baseline LDCT (T0), 376 (42.8%) completed the first round (T1) and 270 (31%) the second (T2) one. Forty-two lung cancers were diagnosed, 30 cancers (71.4%) were stage I or II and 34 cancers (80.9%) were treated surgically. In this study, the overall positive predictive value for a positive screening was 48% (95% CI 37-59) and the negative predictive value 100% (95% CI 100-100).Interpretation: This study demonstrated the feasibility and efficacy of lung cancer screening in a real-life context with most lung cancers diagnosed at an early stage and surgically removed. Our results also highlighted the importance of participation in each round, underlining the fact that optimising organisation is a major goal.Funding: Agence Régionale de Santé de Picardie, La Ligue contre le cancer, le Conseil Départemental de la Somme, and AstraZeneca.","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"109 ","pages":"105396"},"PeriodicalIF":9.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EBioMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ebiom.2024.105396","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In prior randomised controlled trials, lung cancer screening using low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality and overall mortality. Despite these results, organised screening in France remains a challenge. This study assessed the feasibility and efficacy of lung cancer screening within a real-life context in a French administrative territory.

Methods: DEP KP80 was a single-arm prospective study. Participants aged between 55 and 74 years, smokers or former smokers of ≥30 pack-years, were recruited. An annual LDCT scan was scheduled and three rounds were performed. Subjects were selected by general practitioners or pulmonologists, who checked the inclusion criteria and prescribed the CT scan.

Findings: Between March 2016 and February 2020, 1254 participants were enrolled. Overall, 945 (75.4%) participants underwent baseline LDCT (T0), 376 (42.8%) completed the first round (T1) and 270 (31%) the second (T2) one. Forty-two lung cancers were diagnosed, 30 cancers (71.4%) were stage I or II and 34 cancers (80.9%) were treated surgically. In this study, the overall positive predictive value for a positive screening was 48% (95% CI 37-59) and the negative predictive value 100% (95% CI 100-100).

Interpretation: This study demonstrated the feasibility and efficacy of lung cancer screening in a real-life context with most lung cancers diagnosed at an early stage and surgically removed. Our results also highlighted the importance of participation in each round, underlining the fact that optimising organisation is a major goal.

Funding: Agence Régionale de Santé de Picardie, La Ligue contre le cancer, le Conseil Départemental de la Somme, and AstraZeneca.

查看原文本刊更多论文

法国通过低剂量 CT 扫描进行肺癌筛查：DEP KP80 研究三轮后的最终结果。

背景：在之前的随机对照试验中，使用低剂量计算机断层扫描（LDCT）进行肺癌筛查已被证明可降低肺癌死亡率和总死亡率。尽管取得了这些成果，但在法国组织筛查仍是一项挑战。本研究评估了在法国行政区域的实际生活环境中进行肺癌筛查的可行性和有效性：DEP KP80 是一项单臂前瞻性研究。参与者年龄在 55 岁至 74 岁之间，吸烟或曾经吸烟≥30 包年。每年安排一次 LDCT 扫描，共进行了三轮。受试者由全科医生或肺科医生选定，他们会检查纳入标准并开具 CT 扫描处方：结果：2016 年 3 月至 2020 年 2 月期间，共有 1254 名受试者入选。共有 945 人（75.4%）接受了基线 LDCT 扫描（T0），376 人（42.8%）完成了第一轮扫描（T1），270 人（31%）完成了第二轮扫描（T2）。确诊的 42 例肺癌中，30 例（71.4%）为 I 期或 II 期，34 例（80.9%）接受了手术治疗。在这项研究中，筛查阳性的总体阳性预测值为 48%（95% CI 37-59），阴性预测值为 100%（95% CI 100-100）：这项研究证明了肺癌筛查在现实生活中的可行性和有效性，大多数肺癌都能在早期阶段得到诊断并通过手术切除。我们的结果还强调了参与每一轮筛查的重要性，突出了优化组织是主要目标这一事实：资助机构：皮卡第大区卫生局、抗癌联盟、索姆河省议会和阿斯利康公司。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EBioMedicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

17.70

自引率

0.90%

发文量

579

审稿时长

5 weeks

期刊介绍： eBioMedicine is a comprehensive biomedical research journal that covers a wide range of studies that are relevant to human health. Our focus is on original research that explores the fundamental factors influencing human health and disease, including the discovery of new therapeutic targets and treatments, the identification of biomarkers and diagnostic tools, and the investigation and modification of disease pathways and mechanisms. We welcome studies from any biomedical discipline that contribute to our understanding of disease and aim to improve human health.